Does Blue Cross Blue Shield of Arizona Cover Tirzepatide (Mounjaro)?

How BCBSAZ Classifies Tirzepatide on Its Formulary

Blue Cross Blue Shield of Arizona places tirzepatide (Mounjaro) on its formulary for the treatment of type 2 diabetes mellitus. The drug sits on Tier 3 or Tier 4 of the pharmacy benefit, depending on the specific plan design and year of enrollment. This placement means members pay a brand-name copay rather than a generic-level copay, but the drug is not excluded from coverage.

Tirzepatide is a dual GIP/GLP-1 receptor agonist that the FDA approved in May 2022 for glycemic control in adults with type 2 diabetes [1]. In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% from baseline compared to 1.86% with semaglutide 1 mg at 40 weeks [2]. That degree of glucose lowering explains why major insurers, including BCBSAZ, added the drug to covered formularies relatively quickly after approval.

BCBSAZ publishes its formulary lists annually and updates them quarterly. Members can search for Mounjaro on the BCBSAZ formulary lookup tool or call the number on their member ID card to confirm current tier placement. Plan designs purchased through the Health Insurance Marketplace (ACA plans) may have different cost-sharing structures than employer-sponsored group plans, so the tier alone does not determine out-of-pocket cost.

Prior Authorization Requirements

Every BCBSAZ plan requires prior authorization before tirzepatide will be covered. This is standard across nearly all commercial insurers for GLP-1 receptor agonist medications.

To obtain approval, the prescribing clinician must document: a confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x), a current HbA1c level (most plans require HbA1c above 7.0%), evidence that the patient has tried and failed or cannot tolerate metformin for at least 90 days, and confirmation that the patient is not using tirzepatide solely for weight management. Some BCBSAZ plans also require documentation that one additional second-line agent (such as a sulfonylurea or SGLT2 inhibitor) was trialed before approving a GLP-1 receptor agonist.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as preferred second-line therapy for patients with type 2 diabetes who have established cardiovascular disease or high cardiovascular risk, regardless of HbA1c [3]. Dr. Robert Gabbay, ADA Chief Scientific and Medical Officer, stated: "GLP-1 receptor agonists have moved beyond glucose-lowering agents. They are now a cornerstone of cardiorenal risk reduction in type 2 diabetes" [3]. Citing these guidelines in the prior authorization submission can strengthen the case for approval.

PA decisions typically arrive within 48 to 72 hours for standard requests. Urgent requests, where the patient faces imminent health risk from delayed treatment, may receive a response within 24 hours.

Step Therapy: What You Must Try First

Step therapy is the biggest barrier to quick approval. BCBSAZ requires that patients "step through" one or more lower-cost medications before tirzepatide is authorized.

The standard step therapy protocol for Mounjaro on BCBSAZ commercial plans follows this sequence: metformin (first-line, minimum 90-day trial at maximum tolerated dose), then one additional oral agent or injectable GLP-1 receptor agonist (such as dulaglutide or semaglutide), and finally tirzepatide if prior agents did not achieve target HbA1c or caused intolerable side effects. Some employer-sponsored BCBSAZ plans skip the second step and approve tirzepatide after metformin failure alone.

The Endocrine Society's 2023 clinical practice guideline on pharmacologic treatment of type 2 diabetes supports a patient-centered approach to sequencing, noting that "the choice among glucose-lowering medications after metformin should be guided by patient-specific factors including comorbidities, hypoglycemia risk, weight effects, cost, and patient preference" [4]. If the prescribing provider documents a clinical rationale for why tirzepatide is the most appropriate next step (for example, the patient has a BMI above 30, concurrent ASCVD risk factors, and a need for both glycemic and weight reduction), the step therapy requirement can sometimes be overridden through a step therapy exception request.

Patients who have documented allergies, contraindications, or adverse reactions to the required step therapy drugs should ask their provider to submit a formulary exception along with supporting medical records.

Coverage for Weight Loss vs. Type 2 Diabetes

This distinction matters. Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes only. Zepbound (also tirzepatide, same molecule, different brand) is FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity [5].

BCBSAZ commercial plans generally do not cover anti-obesity medications under the pharmacy benefit. Arizona state law does not mandate that commercial insurers cover weight-loss drugs, and most BCBSAZ plan documents explicitly exclude "medications for weight loss or weight management" from the pharmacy formulary. This means that even if a physician prescribes Mounjaro off-label for obesity, BCBSAZ is likely to deny the claim.

However, some self-funded employer plans administered by BCBSAZ do include anti-obesity medication coverage as an optional rider. Members should review their Summary of Benefits and Coverage (SBC) document or contact BCBSAZ member services to determine whether their specific plan includes this benefit.

In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared to 2.4% with placebo [6]. That level of efficacy has pressured insurers nationwide to reconsider exclusions. As of early 2026, a growing number of large employers are adding anti-obesity medication coverage to their BCBSAZ-administered plans, though it remains optional rather than standard.

What You Will Pay Out of Pocket

Cost depends on your plan design, tier placement, and whether you have met your deductible.

For BCBSAZ commercial members with type 2 diabetes who receive PA approval, typical monthly costs range from $25 to $150 per fill. Plans with a $50 brand copay after deductible will cost exactly that once the annual deductible is satisfied. High-deductible health plans (HDHPs) paired with an HSA may require members to pay the full negotiated rate (often $800 to $950 per month) until the deductible is met.

Eli Lilly's Mounjaro Savings Card can reduce the cost to $25 per month for up to 24 months for commercially insured patients. This card does not apply to government-funded insurance (Medicare, Medicaid, TRICARE). Members using BCBSAZ commercial plans are eligible to stack the savings card with their insurance benefit.

Without any insurance coverage, the wholesale acquisition cost of Mounjaro is approximately $1,023 per month [7]. Retail pharmacy cash prices in Arizona range from $1,000 to $1,200 depending on the pharmacy and dose. Lilly's direct-to-patient programs and authorized online pharmacies may offer lower prices for patients paying entirely out of pocket.

BCBSAZ Medicare Advantage members face different cost-sharing. Medicare Part D covers Mounjaro for type 2 diabetes, and under the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective since 2025), Medicare beneficiaries will not pay more than $2,000 total per year across all covered Part D drugs [8]. This cap significantly reduces the financial burden for Medicare Advantage members taking tirzepatide.

How to Appeal a Coverage Denial

A denial is not the final answer. BCBSAZ members have a structured appeals process, and a significant percentage of GLP-1 denials are overturned on appeal when supported by adequate clinical documentation.

The appeals process works in three stages. First, file an internal appeal within 60 days of the denial notice. Include a letter of medical necessity from the prescribing physician, relevant lab results (HbA1c, fasting glucose, lipid panel), documentation of prior medication trials and outcomes, and citations to current clinical guidelines supporting tirzepatide use. Second, if the first-level internal appeal is denied, request a second-level review. BCBSAZ must complete this review within 30 days for non-urgent cases. Third, if both internal appeals fail, members can request an external review through the Arizona Department of Insurance and Financial Institutions. An independent review organization (IRO) will evaluate the case, and its decision is binding on BCBSAZ.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "The prior authorization burden for GLP-1 receptor agonists is among the highest in endocrinology. Clinicians and patients should not accept an initial denial as the end of the conversation" [9]. Including peer-reviewed trial data (such as SURPASS and SURMOUNT outcomes) and ADA guideline citations in the appeal letter improves the likelihood of reversal.

Peer-to-peer review is another option. The prescribing physician can request a direct conversation with the BCBSAZ medical director reviewing the case. This is often the fastest path to overturning a denial, particularly when the clinical rationale is strong but the initial submission lacked documentation.

Comparing BCBSAZ Coverage to Other Arizona Insurers

BCBSAZ is not the only option for Arizona residents seeking tirzepatide coverage. Understanding how competing plans handle the drug can inform open-enrollment decisions.

UnitedHealthcare (UHC) plans in Arizona also cover Mounjaro for type 2 diabetes with prior authorization and step therapy. Aetna's Arizona formularies include tirzepatide on Tier 3 with similar PA requirements. Cigna places Mounjaro on its National Preferred Formulary but requires both prior authorization and step therapy through metformin and one additional oral agent.

For obesity coverage specifically, the Arizona Health Care Cost Containment System (AHCCCS, Arizona's Medicaid program) does not cover anti-obesity medications for adults. Medicare Part D covers Mounjaro for diabetes but not Zepbound for weight management, as Medicare statute has historically excluded weight-loss drugs, though legislative efforts to change this exclusion (the Treat and Reduce Obesity Act) remain active in Congress as of 2026.

The key differentiator among Arizona insurers is not whether they cover tirzepatide for diabetes (most do) but how burdensome the step therapy and PA process is. BCBSAZ's requirement of 90 days of metformin plus potentially one additional agent is on the stricter end compared to some UHC plans that accept metformin intolerance documentation without a mandatory 90-day trial period.

Tips for Getting Approved Faster

Preparation makes the difference between a smooth approval and months of back-and-forth.

Start with complete documentation. Before the provider submits the PA, gather three months of HbA1c results, a medication history showing metformin trial dates and outcomes, body weight records, and a list of comorbidities (hypertension, dyslipidemia, ASCVD history, CKD staging). The more complete the initial submission, the less likely BCBSAZ will request additional information and delay the decision.

Ask the prescribing provider to use diagnosis-specific language. Phrasing the request around "inadequate glycemic control despite maximally tolerated metformin" rather than "patient would like to try Mounjaro" aligns with BCBSAZ's medical policy language and reduces friction.

Use electronic prior authorization (ePA) when available. Many BCBSAZ plans support ePA through platforms like CoverMyMeds or Surescripts, which auto-populate required clinical fields and can reduce turnaround time from 72 hours to under 24 hours.

If the patient qualifies for both diabetes and weight management indications, the provider should submit the PA under the type 2 diabetes indication. Coverage is far more likely under the diabetes benefit, and the weight-reduction benefits of tirzepatide will occur regardless of which indication is listed on the prescription.

The SURPASS-4 trial (N=2,002) demonstrated that tirzepatide provided sustained HbA1c reductions of 2.24% at 104 weeks versus 1.48% with insulin glargine, with the added benefit of 12.9% weight loss versus 2.2% weight gain [10]. Including this long-term efficacy data in the PA submission supports the argument that tirzepatide provides durable benefit beyond what insulin therapy can achieve.